ADPD | Acumen Pharmaceuticals

ADPD 2025 Poster

2025 ADPD Poster:

Utility of Human iPSC-derived Neuronal Model for Evaluating Synaptic Binding of Aβ Oligomers

2025 ADPD Poster:

Preparing Stable Monomeric Aβ to Assess AβO Selectivity Assays

2024 ADPD Presentation:

Sabirnetug (ACU193) Lowers CSF Neurogranin & pTau181 Levels in INTERCEPT-AD Study in Early AD.

Target Engagement in INTERCEPT-AD: Development of a Novel Assay Measuring Sabirnetug (ACU193)-Amyloid Βeta Oligomer Complexes in Human CSF.

2023 ADPD Poster:

Binding of Soluble Amyloid Beta Oligomer Species to Human IPSC-derived Excitatory Neurons Assessed Using a Panel of AB Antibodies.